Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials

Author List
Kimberly Struble
Kirk Chan-Tack
Karen Qi
Thamban Valappil
Sarah Connelly
Poonam Mishra
Dionne Price
Jeffrey Murray
Debra Birnkrant

Abstract

Under representation of black subjects in trials of hepatitis C virus (HC V) direct-acting antivirals (DAA s) complicates assessment of differential outcomes for black individuals vs non-black individuals. HC V trials submitted to the Food and Drug Administration (2013–2017) to support approval or to expand an indication of 12-week interferon-free DAA regimens with or without ribavirin to treat HC V genotype 1 (GT1) infection were pooled to explore efficacy comparisons by ethnicity.

Article Category

Hepatitis C (HCV)

Article Type

Original research

Posted Date

19-09-2019

Tables & Figures

Back to top